Respiratory syncytial virus: A continuing culprit and conundrum

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Respiratory syncytial virus (RSV) is a major global pathogen responsible for substantial infant hospitalizations and healthcare costs in the U.S.
• RSV infections lead to predictable annual outbreaks and lifelong recurrent infections, posing challenges for control.
• High-risk populations include young infants (especially premature), individuals with chronic pulmonary/cardiac conditions, and immunocompromised patients.

Purpose of the Study:

• To review the challenges and current strategies for controlling respiratory syncytial virus (RSV) infections.
• To discuss the requirements for an effective RSV vaccine and existing prophylactic and therapeutic options.

Main Methods:

• Literature review of RSV epidemiology, disease burden, and control measures.
• Analysis of current prophylactic and therapeutic interventions for RSV.
• Discussion of the criteria for successful RSV vaccine development.

Main Results:

• RSV infections result in significant morbidity and mortality, particularly in vulnerable populations.
• Existing control measures include RSV immune globulin and a monoclonal antibody for prophylaxis in high-risk infants.
• Therapeutic options for RSV are limited, with a combination of immune globulin and ribavirin explored for immunocompromised patients.

Conclusions:

• Effective control of RSV requires a vaccine administered early in life that surpasses natural immunity.
• Prophylaxis and supportive care are current mainstays, but therapeutic options remain limited and controversial.
• Ongoing development of candidate RSV vaccines aims to address the significant public health burden of this virus.